Terns Pharmaceuticals Ownership | Who Owns Terns Pharmaceuticals?


Terns Pharmaceuticals Ownership Summary


Terns Pharmaceuticals is owned by 105.30% institutional investors, 0.26% insiders. Soleus capital management is the largest institutional shareholder, holding 10.46% of TERN shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.44% of its assets in Terns Pharmaceuticals shares.

TERN Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockTerns Pharmaceuticals105.30%0.26%-5.56%
SectorHealthcare Stocks 56.95%9.26%33.79%
IndustryBiotech Stocks 68.60%8.88%22.52%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Soleus capital management8.14M10.46%$45.11M
Orbimed advisors7.56M9.72%$41.90M
Vivo capital6.90M8.86%$38.20M
Blackrock funding, inc. /de5.74M7.38%$31.82M
Deep track capital, lp5.58M7.17%$30.89B
Schonfeld strategic advisors4.75M6.11%$26.32M
Blackrock4.12M5.53%$28.06M
Vanguard group3.87M4.97%$21.44M
Nuveen asset management2.63M3.38%$14.59M
Candriam s.c.a.2.15M2.77%$11.93M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Superstring capital management lp2.02M9.69%$11.19M
Vivo capital6.90M4.28%$38.20M
Soleus capital management8.14M2.83%$45.11M
Acuta capital partners447.50K2.49%$2.48B
Timessquare capital management621.64K1.45%$92.18M
Robeco schweiz411.27K1.17%$60.99M
Deep track capital, lp5.58M1.15%$30.89B
Orbimed advisors7.56M0.86%$41.90M
Altium capital management lp475.00K0.75%$2.63M
Parkman healthcare partners829.11K0.61%$4.59M

Top Buyers

HolderShares% AssetsChange
Candriam s.c.a.2.15M0.07%2.15M
Soleus capital management8.14M2.83%1.92M
Schonfeld strategic advisors4.75M0.15%1.46M
Blackrock funding, inc. /de5.74M0.00%1.04M
Norges bank849.39K0.00%849.39K

Top Sellers

HolderShares% AssetsChange
Vr adviser1.08M0.41%-2.33M
Avidity partners management lp---2.13M
Janus henderson group---2.00M
Exoduspoint capital management, lp10.82K0.00%-1.64M
Point72 asset management1.25M0.02%-1.46M

New Positions

HolderShares% AssetsChangeValue
Candriam s.c.a.2.15M0.07%2.15M$11.93M
Norges bank849.39K0.00%849.39K$4.71M
Bnp paribas arbitrage, snc224.26K0.00%224.26K$1.24M
Hightower advisors84.43K0.00%84.43K$467.74K
Crestline management, lp66.60K0.01%66.60K$368.96K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-9.00
Pnc financial services group-17.00
Capital performance advisors llp-23.00
Lindbrook capital-63.00
Allworth financial lp-90.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2024149-9.70%81,944,1563.09%1051.01%94-8.74%31-18.42%
Sep 30, 202416517.86%79,491,27019.38%1021.28%1038.42%3865.22%
Jun 30, 202414019.66%66,584,8335.52%891.24%9548.44%23-28.13%
Mar 31, 20241176.36%63,102,304-0.76%841.10%644.92%3239.13%
Dec 31, 202311012.24%63,584,9993.76%871.20%6148.78%23-36.11%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.07M2.44%-
iShares Russell 2000 ETF1.88M2.21%-14.25K
CREF Stock R11.42M1.67%-
Belfius Equities Cure C Cap1.29M1.51%-
Fidelity Select Biotechnology1.09M1.29%1.09M
US Small-Cap Growth II Equity Comp1.04M1.23%529.45K
T. Rowe Price New Horizons1.04M1.23%-
Vanguard Institutional Extnd Mkt Idx Tr936.74K1.10%254.79K
Fidelity Small Cap Growth877.41K1.04%-1.09M
Candriam Eqs L Biotech C USD Cap868.73K1.02%868.73K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 30, 2024Jung Melita Sun Chief Business OfficerBuy$11.50K
Nov 30, 2024Burroughs Amy L. Chief Executive OfficerBuy$2.61K
Jan 02, 2025Kuriakose Emil Chief Medical OfficerSell$25.61K
Jan 06, 2025Vignola Mark J. Chief Financial OfficerSell$52.50K
Jan 02, 2025Vignola Mark J. Chief Financial OfficerSell$46.52K

Insider Transactions Trends


DateBuySell
2025 Q1-5
2024 Q41-
2024 Q3218
2024 Q229
2024 Q1--

TERN Ownership FAQ


Who Owns Terns Pharmaceuticals?

Terns Pharmaceuticals shareholders are primarily institutional investors at 105.30%, followed by 0.26% insiders and -5.56% retail investors. The average institutional ownership in Terns Pharmaceuticals's industry, Biotech Stocks , is 68.60%, which Terns Pharmaceuticals exceeds.

Who owns the most shares of Terns Pharmaceuticals?

Terns Pharmaceuticals’s largest shareholders are Soleus capital management (8.14M shares, 10.46%), Orbimed advisors (7.56M shares, 9.72%), and Vivo capital (6.9M shares, 8.86%). Together, they hold 29.04% of Terns Pharmaceuticals’s total shares outstanding.

Does Blackrock own Terns Pharmaceuticals?

Yes, BlackRock owns 5.53% of Terns Pharmaceuticals, totaling 4.12M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 28.06M$. In the last quarter, BlackRock increased its holdings by 804.98K shares, a 24.28% change.

Who is Terns Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Superstring capital management lp is Terns Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 9.69% of its assets in 2.02M Terns Pharmaceuticals shares, valued at 11.19M$.

Who is the top mutual fund holder of Terns Pharmaceuticals shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Terns Pharmaceuticals shares, with 2.44% of its total shares outstanding invested in 2.07M Terns Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools